Arcus Biosciences (RCUS) news
Recent news
Arcus Biosciences Q2 EPS USD -0.72
AInvest Wire · Aug 5, 2026Arcus Biosciences Q2 revenue USD 41 million vs. IBES estimate USD 23.4 million
AInvest Wire · Aug 5, 2026Arcus Biosciences - enrollment for new ARC-20 cohort expected to begin in Q4 2026
Arcus Biosciences is preparing to initiate enrollment for the ARC-20 cohort in the fourth quarter of 2026, as part of its ongoing clinical development program for AB521, a potential therapeutic candidate for advanced solid tumor malignancies and clear cell renal cell carcinoma. The ARC-20 cohort…
AInvest Wire · Jul 22, 2026Arcus Biosciences announces clinical supply agreement with Aveo Oncology to evaluate casdatifan in combination with tivozanib for advanced kidney cancer patients
Arcus Biosciences has entered into a clinical trial collaboration and supply agreement with Aveo Oncology to evaluate HIF-2α inhibitor casdatifan in combination with tivozanib, a PDL1VEGFA bispecific immunomodulator, for the treatment of advanced kidney cancer patients. This partnership aims to…
AInvest Wire · Jul 22, 2026Arcus Biosciences Inc: Both cos will contribute to cost of study, each co will retain development & commercial rights to their respective molecules
Arcus Biosciences Inc. has announced a collaborative agreement in which both parties will share the costs associated with a joint study. Under the terms of the agreement, each company will retain full development and commercial rights to their respective molecules, ensuring that neither party cedes…
AInvest Wire · Jul 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.